049960.Kq
The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
Business. The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
The company maintains a strong capital structure, with a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. Its liquidity position is characterized as medium, with a current ratio of 21.34, suggesting a high level of short-term liquidity. However, the company has a negative net cash position after subtracting total debt, which may raise concerns about its ability to meet short-term obligations.
In terms of profitability, the company demonstrates a return on equity (ROE) of 7.69% and a return on assets (ROA) of 7.41%, both of which are strong indicators of efficient use of equity and assets. These figures suggest the company is performing well relative to industry standards, although specific comparisons to cohort medians are not available in the provided data.
The company's revenue is not segmented by geographic region or product line in the available data, so it is not possible to assess revenue concentration or geographic exposure. However, the absence of detailed segment data may indicate a relatively concentrated business model or a lack of public disclosure on this matter.
The company's growth trajectory is not explicitly outlined in the provided data, but its strong operating and net income figures suggest a stable and potentially growing business. The absence of detailed outlook data for the current and next fiscal years limits the ability to assess future growth expectations.
The company's risk profile is characterized by a low dilution potential and a medium liquidity risk. The negative net cash position after subtracting total debt is a key flag, indicating potential liquidity constraints. No specific dilution sources are identified in the provided data, and the likelihood of near-term dilution is assessed as low.
Recent events, such as filings and transcripts, are not detailed in the provided data, so it is not possible to assess the impact of recent developments on the company's financial position or strategic direction.
- The company has a strong capital structure with no long-term debt and a high current ratio.
- The company's profitability is robust, with a high return on equity and return on assets.
- The company's liquidity position is medium, with a negative net cash position after subtracting total debt.
- The company's risk profile is characterized by low dilution potential and medium liquidity risk.
- The company's growth trajectory is not explicitly outlined, but its strong operating and net income figures suggest a stable and potentially growing business.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 049960.KQ Market data — financials · 2026-05-26